Coeptis Therapeutics to Acquire Allogeneic Immuno-Oncology NK Platform in Ph 1 Trials from Deverra Therapeutics April 27, 2023
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients April 27, 2023
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology April 27, 2023
Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned April 27, 2023
Positive final results from Ph 2 trial of VB10.16 + atezolizumab in advanced cervical cancer announced April 27, 2023
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA April 27, 2023
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed R/R Multiple Myeloma April 27, 2023
U.S. FDA Accepts for Priority Review Supplemental NDA for the Use of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory mCRC April 27, 2023
FDA approves Polivy in combination with R-CHP for people with certain types of 1L DLBCL April 27, 2023
